# Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation

> **NCT00918346** · PHASE3 · COMPLETED · sponsor: **Santen Oy** · enrollment: 43 (actual)

## Conditions studied

- Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Tafluprost 0.0015%

## Key facts

- **NCT ID:** NCT00918346
- **Lead sponsor:** Santen Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-03
- **Final completion:** 2006-04
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2010-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918346, "Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00918346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*